Cantor Fitzgerald Reaffirms “Overweight” Rating for Agios Pharmaceuticals (NASDAQ:AGIO)

Agios Pharmaceuticals (NASDAQ:AGIO)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a research report issued to clients and investors on Wednesday,Benzinga reports.

A number of other equities analysts also recently weighed in on the stock. Royal Bank of Canada boosted their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. Scotiabank increased their target price on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research report on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and issued a $51.00 price target on shares of Agios Pharmaceuticals in a report on Thursday, October 10th. StockNews.com upgraded Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, November 9th. Finally, Leerink Partnrs lowered Agios Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, September 27th. Five analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $56.33.

Agios Pharmaceuticals Trading Down 1.7 %

Shares of NASDAQ:AGIO opened at $41.96 on Wednesday. The stock has a market cap of $2.39 billion, a PE ratio of 3.69 and a beta of 0.80. The stock’s fifty day simple moving average is $50.09 and its two-hundred day simple moving average is $46.84. Agios Pharmaceuticals has a 1-year low of $20.96 and a 1-year high of $62.58.

Insider Buying and Selling

In other news, CFO Cecilia Jones sold 2,542 shares of the company’s stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $49.03, for a total value of $124,634.26. Following the completion of the sale, the chief financial officer now owns 20,158 shares of the company’s stock, valued at approximately $988,346.74. This represents a 11.20 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 4.93% of the stock is owned by company insiders.

Institutional Trading of Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AGIO. Acadian Asset Management LLC bought a new position in Agios Pharmaceuticals during the 2nd quarter valued at approximately $37,000. Quest Partners LLC purchased a new stake in Agios Pharmaceuticals in the second quarter worth $40,000. Mirae Asset Global Investments Co. Ltd. boosted its holdings in Agios Pharmaceuticals by 21.4% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,058 shares of the biopharmaceutical company’s stock valued at $94,000 after acquiring an additional 363 shares in the last quarter. CWM LLC increased its position in Agios Pharmaceuticals by 554.7% during the 3rd quarter. CWM LLC now owns 2,167 shares of the biopharmaceutical company’s stock valued at $96,000 after purchasing an additional 1,836 shares during the period. Finally, Quantbot Technologies LP bought a new position in Agios Pharmaceuticals in the 3rd quarter worth $146,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.